Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MEREO BIOPHARMA GROUP PLC

(MREO)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
07/19/2021 07/20/2021 07/21/2021 07/22/2021 07/23/2021 Date
2.77(c) 2.85(c) 2.82(c) 2.77(c) 2.5 Last
1 318 790 812 132 1 181 403 1 420 875 4 682 342 Volume
-2.12% +2.89% -1.05% -1.77% -9.75% Change
More quotes
Estimated financial data (e)
Sales 2021 12,1 M 16,6 M 16,6 M
Net income 2021 -32,1 M -44,2 M -44,2 M
Net cash position 2021 102 M 140 M 140 M
P/E ratio 2021 -33,5x
Yield 2021 -
Sales 2022 - - -
Net income 2022 -61,8 M -85,0 M -85,0 M
Net cash position 2022 61,4 M 84,4 M 84,4 M
P/E ratio 2022 -19,5x
Yield 2022 -
Capitalization 217 M 299 M 299 M
EV / Sales 2021 9,57x
EV / Sales 2022 -
Nbr of Employees 38
Free-Float 89,1%
More Financials
Company
Mereo BioPharma Group PLC is a United Kingdom-based biopharmaceutical company. The Company is focused on developing and commercializing new therapies for rare disease patients, focusing on bone/musculoskeletal, respiratory and endocrine indications. Its pipeline consists of a diversified portfolio of clinical-stage product candidates, including BPS-804 (setrusumab) for the treatment of osteogenesis imperfecta (OI);... 
More about the company
Ratings of Mereo BioPharma Group plc
Trading Rating : 
Investor Rating :  -
ESG Refinitiv : 
-
More Ratings
All news about MEREO BIOPHARMA GROUP PLC
07/21European ADRs Move Sharply Higher in Wednesday Trading
MT
07/20MEREO BIOPHARMA : Letter of Ernst & Young LLP, dated July 20, 2021 (Form 6-K)
PU
07/16European ADRs Move Lower in Friday Trading
MT
07/13European ADRs Move Lower in Tuesday Trading
MT
07/09European ADRs Move Sharply Higher in Friday Trading
MT
06/29European ADRs Move Lower in Tuesday Trading
MT
06/24European ADRs Move Higher in Thursday Trading
MT
06/23European ADRs Edge Higher in Wednesday Trading
MT
06/22European ADRs Move Lower in Tuesday Trading
MT
06/21European ADRs Move Higher in Monday Trading
MT
06/18European ADRs Down More Than 2% Friday as Banks, Drillers Drop
MT
06/16European ADRs Flat in Wednesday Morning Trading
MT
06/15European ADRs Flat in Tuesday Trading
MT
06/14European ADRs Move Higher in Monday Trading
MT
06/10European ADRs Move Higher in Thursday Trading
MT
More news
News in other languages on MEREO BIOPHARMA GROUP PLC

- No features available -

More news
Analyst Recommendations on MEREO BIOPHARMA GROUP PLC
More recommendations
Chart MEREO BIOPHARMA GROUP PLC
Duration : Period :
Mereo BioPharma Group plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MEREO BIOPHARMA GROUP PLC
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Last Close Price 201,12 GBX
Average target price 669,97 GBX
Spread / Average Target 233%
EPS Revisions
Managers and Directors
Denise Vera Scots-Knight Chief Executive Officer & Director
Christine Fox Chief Financial Officer
Peter John Fellner Independent Non-Executive Chairman
John A. Lewicki Chief Scientific Officer
Ann Kapoun Senior VP-Translational Research & Development
Sector and Competitors
1st jan.Capi. (M$)
MEREO BIOPHARMA GROUP PLC-22.63%346
GILEAD SCIENCES, INC.17.83%85 134
WUXI APPTEC CO., LTD.37.17%71 226
REGENERON PHARMACEUTICALS21.48%57 013
BIONTECH SE244.68%55 555
VERTEX PHARMACEUTICALS-17.06%50 308